Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ADVM

Adverum Biotechnologies Inc

Apr 23 • 04:00PM ET

11.00

Dollar change -0.34
Percentage change -3.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAC ITOT FESM DFAS DFSU DCOR DFUS AVSC

Index	-	P/E	-	EPS (ttm)	-11.62	Insider Own	27.84%	Shs Outstand	20.75M	Perf Week	-5.25%
Market Cap	228.25M	Forward P/E	-	EPS next Y	-5.52	Insider Trans	4.15%	Shs Float	14.98M	Perf Month	-31.51%
Income	-117.17M	PEG	-	EPS next Q	-1.41	Inst Own	33.23%	Short Float	5.94%	Perf Quarter	27.31%
Sales	3.60M	P/S	63.40	EPS this Y	48.81%	Inst Trans	-	Short Ratio	3.23	Perf Half Y	14.55%
Book/sh	8.23	P/B	1.34	EPS next Y	7.02%	ROA	-48.68%	Short Interest	0.89M	Perf Year	18.28%
Cash/sh	4.65	P/C	2.36	EPS next 5Y	-	ROE	-88.43%	52W Range	7.10 - 29.70	Perf YTD	46.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.36%	ROI	-79.11%	52W High	-62.96%	Beta	0.85
Dividend TTM	-	Quick Ratio	4.13	Sales past 5Y	-56.90%	Gross Margin	-249.44%	52W Low	54.93%	ATR (14)	1.03
Dividend Ex-Date	-	Current Ratio	4.13	EPS Y/Y TTM	25.38%	Oper. Margin	-3438.64%	RSI (14)	27.73	Volatility	5.25% 6.36%
Employees	121	Debt/Eq	0.90	Sales Y/Y TTM	-	Profit Margin	-3254.58%	Recom	1.33	Target Price	40.00
Option/Short	Yes / Yes	LT Debt/Eq	0.77	EPS Q/Q	28.49%	Payout	-	Rel Volume	1.11	Prev Close	11.34
Sales Surprise	-	EPS Surprise	31.52%	Sales Q/Q	-	Earnings	Mar 18 AMC	Avg Volume	275.49K	Price	11.00
SMA20	-13.02%	SMA50	-32.67%	SMA200	-20.92%	Trades		Volume	305,048	Change	-3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-22	Upgrade	Truist	Hold → Buy	$4
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Apr-29-21	Downgrade	Truist	Buy → Hold	$30 → $9
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Dec-16-20	Initiated	UBS	Neutral	$13
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform	$24
May-05-20	Upgrade	SunTrust	Hold → Buy	$13 → $21
Apr-28-20	Initiated	Goldman	Buy	$17
Mar-16-20	Initiated	SVB Leerink	Outperform	$17
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$20
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$8 → $21
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral	$6 → $10
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral	$10 → $6
Jun-14-19	Resumed	Raymond James	Mkt Perform
Nov-02-18	Downgrade	SunTrust	Buy → Hold
Nov-02-18	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Today 09:40AM	Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-19-24 09:35AM	Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Apr-04-24 09:40AM	Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? (Zacks)
08:34AM	How Adverum (ADVM) Stock Stands Out in a Strong Industry (Zacks)
Apr-03-24 09:35AM	Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround (Zacks)
09:35AM	Loading…
Mar-27-24 09:35AM	Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) (Zacks)
Mar-21-24 07:52AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Mar-20-24 05:33AM	Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments (GuruFocus.com) -7.88%
Mar-19-24 09:40AM	Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.78%
Mar-18-24 10:53PM	ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023 (InvestorPlace)
04:20PM	Adverum Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates (GlobeNewswire)
Mar-06-24 03:07PM	Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop (InvestorPlace)
Feb-28-24 04:05PM	Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-27-24 06:10AM	Stocks on the Launchpad: The Next 3 Market Sensations (InvestorPlace)
06:15AM	Loading…
Feb-22-24 06:15AM	Unleash Massive Returns With These 3 Top Penny Stocks (InvestorPlace) +6.60%
Feb-12-24 08:00AM	Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +15.03%
Feb-08-24 07:00AM	Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD (GlobeNewswire) -29.89%
Feb-05-24 07:45AM	Adverum Biotechnologies Announces $127.5 Million Private Placement Financing (GlobeNewswire) +34.51%
Feb-01-24 05:30PM	Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 (GlobeNewswire) +13.33%
Jan-29-24 08:00AM	Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer (GlobeNewswire) +13.89%
Jan-04-24 08:27AM	Here's Why You Should Invest in Adverum (ADVM) Stock Now (Zacks) +6.00%
Dec-07-23 04:05PM	Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society (GlobeNewswire) +9.43%
Nov-28-23 04:05PM	Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-23 04:51PM	Adverum Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire)
Nov-06-23 08:00AM	Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors (GlobeNewswire)
Nov-04-23 05:54PM	Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-26-23 04:05PM	Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial (GlobeNewswire) +7.50%
04:05PM	Loading…
Sep-21-23 04:05PM	Adverum Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:05PM	Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer (GlobeNewswire)
Aug-14-23 08:00AM	Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Aug-10-23 04:20PM	Adverum Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-12-23 08:00AM	Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid (GlobeNewswire)
Jun-02-23 08:00AM	Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +6.14%
May-25-23 06:30AM	Adverum Biotechnologies Announces New Executive Leadership Roles (GlobeNewswire) +7.41%
May-18-23 09:00AM	Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vecs Phase 2 Clinical Development at ASGCT 2023 Annual Meeting (GlobeNewswire)
09:00AM	Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform (GlobeNewswire)
May-11-23 04:47PM	Adverum Biotechnologies: Q1 Earnings Snapshot (AP Finance)
04:05PM	Adverum Biotechnologies Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 04:05PM	Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.20%
May-02-23 04:30PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD (GlobeNewswire) -7.42%
Apr-23-23 01:00PM	Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec (GlobeNewswire)
Apr-21-23 06:03AM	After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain (Simply Wall St.) -7.00%
Apr-18-23 08:00AM	Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD (GlobeNewswire)
Apr-17-23 04:05PM	Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting (GlobeNewswire)
Apr-04-23 09:40AM	Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-30-23 04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update (GlobeNewswire)
Mar-02-23 10:23AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
Feb-27-23 04:05PM	Adverum Biotechnologies to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-18-23 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 04:05PM	Adverum Biotechnologies Reports Third Quarter 2022 Financial Results (GlobeNewswire) +7.57%
Nov-04-22 12:08PM	Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022) (GlobeNewswire)
Oct-27-22 04:05PM	Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting (GlobeNewswire)
Sep-30-22 04:45PM	Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD (GlobeNewswire)
Sep-27-22 04:05PM	Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-23-22 04:05PM	Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
11:06AM	Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation (Simply Wall St.)
08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022 (GlobeNewswire)
Sep-15-22 05:19PM	Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study (Zacks)
Sep-14-22 08:00AM	Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Sep-08-22 04:05PM	Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-26-22 04:05PM	Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-11-22 04:05PM	Adverum Biotechnologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 04:05PM	Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Aug-01-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.48%
Jul-25-22 07:16AM	Quite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders (Simply Wall St.)
Jul-15-22 09:52AM	Adverum Posts New Data From Wet AMD Gene Therapy Trial (Benzinga) -5.71%
08:32AM	Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD (GlobeNewswire)
Jul-08-22 08:00AM	Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022 (GlobeNewswire) +9.29%
Jul-07-22 05:14PM	Gene therapy company cuts 78 jobs as it jump-starts program in blinding eye disease (American City Business Journals) +13.82%
11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
08:02AM	Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022 (Benzinga)
Jul-06-22 04:05PM	Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD (GlobeNewswire) +6.03%
09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire)
Jun-24-22 08:00AM	Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD (GlobeNewswire)
Jun-09-22 08:00AM	Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD (GlobeNewswire)
Jun-02-22 04:05PM	Adverum Biotechnologies Announces New Data at the Macula Societys 2022 Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy (GlobeNewswire)
May-18-22 08:11AM	Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy (Benzinga)
May-17-22 04:05PM	Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022 (GlobeNewswire)
May-12-22 04:05PM	Adverum Biotechnologies Reports First Quarter 2022 Financial Results (GlobeNewswire) -6.58%
May-11-22 02:51PM	How Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own? (Simply Wall St.) -9.09%
May-09-22 04:05PM	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-22 04:30PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022 (GlobeNewswire)
06:59AM	Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD (Benzinga)
May-01-22 02:15PM	Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting (GlobeNewswire)
Apr-19-22 06:00PM	Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022 (GlobeNewswire)
Apr-07-22 02:50PM	Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study (Zacks)
07:30AM	Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD (Benzinga)
Apr-06-22 04:05PM	Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA (GlobeNewswire)
Mar-29-22 04:05PM	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-17-22 04:05PM	Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors (GlobeNewswire) +6.30%
Mar-02-22 12:11PM	Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings? (Zacks)
Feb-28-22 08:00AM	Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-15-22 04:22AM	Insiders who bought in the last 12 months lose an additional US$367k as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$136m (Simply Wall St.)

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lupher, Jr. Mark L.	Director	Feb 07 '24	Buy	1.35	130,000	175,500	130,000	Feb 09 05:50 PM
Scopa James Paul	Director	Feb 07 '24	Buy	1.35	100,000	135,000	100,000	Feb 09 05:51 PM
Seyedkazemi Setareh	Chief Development Officer	Sep 15 '23	Sale	1.52	6,201	9,429	47,674	Sep 18 06:54 PM
Rubinstein Linda M	Chief Financial Officer	Jun 07 '23	Buy	1.45	100,000	145,490	100,000	Jun 09 04:26 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Apr 23 • 04:00PM ET

24.42

Dollar change +0.25
Percentage change 1.03	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWO LABU SCHA VHT VTWO SURI

Index	RUT	P/E	-	EPS (ttm)	-4.03	Insider Own	21.46%	Shs Outstand	46.72M	Perf Week	1.71%
Market Cap	1.14B	Forward P/E	65.49	EPS next Y	0.37	Insider Trans	-0.31%	Shs Float	36.61M	Perf Month	-6.54%
Income	-160.91M	PEG	-	EPS next Q	-0.42	Inst Own	91.40%	Short Float	22.29%	Perf Quarter	-7.81%
Sales	186.37M	P/S	6.11	EPS this Y	70.84%	Inst Trans	11.41%	Short Ratio	16.27	Perf Half Y	-15.50%
Book/sh	5.32	P/B	4.59	EPS next Y	132.46%	ROA	-32.20%	Short Interest	8.16M	Perf Year	-10.42%
Cash/sh	6.14	P/C	3.98	EPS next 5Y	-	ROE	-82.37%	52W Range	23.29 - 35.56	Perf YTD	-17.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.57%	ROI	-28.95%	52W High	-31.33%	Beta	1.14
Dividend TTM	-	Quick Ratio	4.19	Sales past 5Y	88.90%	Gross Margin	75.98%	52W Low	4.85%	ATR (14)	0.96
Dividend Ex-Date	-	Current Ratio	4.45	EPS Y/Y TTM	-0.28%	Oper. Margin	-57.22%	RSI (14)	42.12	Volatility	3.10% 3.55%
Employees	264	Debt/Eq	1.24	Sales Y/Y TTM	141.85%	Profit Margin	-86.33%	Recom	1.10	Target Price	50.50
Option/Short	Yes / Yes	LT Debt/Eq	1.23	EPS Q/Q	28.44%	Payout	-	Rel Volume	0.84	Prev Close	24.17
Sales Surprise	2.49%	EPS Surprise	-162.39%	Sales Q/Q	149.24%	Earnings	Feb 28 AMC	Avg Volume	501.57K	Price	24.42
SMA20	-2.28%	SMA50	-9.03%	SMA200	-13.24%	Trades		Volume	423,071	Change	1.03%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Apr-10-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 08:30AM	Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canadas CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome (Business Wire)
Mar-29-24 11:30AM	Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-25-24 11:46PM	Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares (GuruFocus.com)
07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
09:32AM	Loading…
Mar-15-24 09:32AM	Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use (Zacks)
Mar-13-24 06:00PM	Mirum Pharmaceuticals LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (Business Wire)
Mar-08-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-29-24 11:34AM	Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat (Zacks)
09:49AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:30AM	Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirums LIVMARLI (Business Wire)
Feb-28-24 05:35PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:38PM	Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ... (GuruFocus.com)
04:03PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update (Business Wire)
04:05PM	Loading…
Feb-21-24 04:05PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 (Business Wire)
Feb-09-24 09:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-23-24 11:44AM	Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback (Zacks)
Jan-19-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-16-24 08:30AM	Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer (Business Wire)
Jan-15-24 04:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.91%
Jan-08-24 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates (Business Wire)
Jan-03-24 08:45AM	Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 01:05PM	United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023 (Associated Press Finance) -15.87%
08:37AM	Mirum Pharma's liver disease therapy fails in mid-stage study (Reuters)
08:30AM	Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia (Business Wire)
Dec-08-23 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
04:05PM	Loading…
Nov-20-23 04:05PM	Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 02:00PM	Mirum Pharmaceuticals Presents New Data at The Liver Meeting (Business Wire) +6.57%
Nov-10-23 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-23 09:10AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference (Business Wire) +5.67%
Nov-02-23 07:13PM	Mirum Pharmaceuticals Inc (MIRM) Reports Q3 2023 Revenue of $47.7 Million, Up 154% YoY (GuruFocus.com)
04:05PM	Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-30-23 10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Mirum Pharmaceuticals to Present New Data at The Liver Meeting (Business Wire)
Oct-27-23 08:45AM	Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (Business Wire)
Oct-17-23 04:30PM	Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (Business Wire)
Oct-11-23 04:52PM	7 Small-Cap Stocks That Get the Nod from Wall Street (InvestorPlace) -5.79%
Oct-10-23 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-23 05:00PM	Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN (Business Wire)
Oct-02-23 08:30AM	Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis (Business Wire) -7.28%
Sep-26-23 08:30AM	Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Sep-21-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire)
Sep-15-23 03:05PM	Director Michael Grey Sells 14,608 Shares of Mirum Pharmaceuticals Inc (MIRM) (GuruFocus.com)
08:30AM	Mirum Pharmaceuticals Merits a Healthy Endorsement Based on Its Charts (TheStreet.com)
06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Sep-14-23 01:15PM	Director Patrick Heron Buys 8,437 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com) +8.01%
Sep-13-23 01:01PM	Insider Buying: CFO Eric Bjerkholt Acquires 10,000 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 10:07AM	Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer (Business Wire)
Sep-08-23 11:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-23 11:19AM	Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-10-23 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-03-23 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-27-23 04:05PM	Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 (Business Wire)
Jul-25-23 05:12PM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks)
08:30AM	Mirums LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire)
Jul-20-23 08:18AM	With 67% institutional ownership, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a favorite amongst the big guns (Simply Wall St.)
Jul-18-23 10:48AM	With $445 million deal, Peninsula company restocks for another run with a late-stage drug (American City Business Journals)
Jul-17-23 02:18PM	Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation (Benzinga)
08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-10-23 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-23 09:27AM	Investors push Mirum Pharmaceuticals (NASDAQ:MIRM) 11% lower this week, company's increasing losses might be to blame (Simply Wall St.)
Jun-23-23 12:00PM	Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress (Business Wire)
Jun-14-23 08:30AM	Event-Free Survival Data from Mirums LIVMARLI Alagille Syndrome Program Published in Hepatology (Business Wire) -5.85%
Jun-09-23 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-23 08:30AM	Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress (Business Wire)
Jun-02-23 08:49AM	There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price (Simply Wall St.)
May-19-23 07:00AM	Data from Mirums LIVMARLI Studies Presented at ESPGHAN Annual Meeting (Business Wire)
May-18-23 08:30AM	Hepatology Communications Publishes Data from Mirums LIVMARLI in Primary Sclerosing Cholangitis (Business Wire)
May-17-23 08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting (Business Wire)
May-11-23 08:30AM	Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study (Business Wire)
May-10-23 09:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 02:59PM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-06-23 08:05AM	Mirum Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-04-23 06:05PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 10:00AM	VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-27-23 04:02PM	Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 (Business Wire)
10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-25-23 05:44AM	Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength? (Zacks)
Apr-18-23 06:15AM	Industry Analysts Just Made A Meaningful Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts (Simply Wall St.)
Apr-13-23 12:15AM	Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering (Business Wire) +5.44%
Apr-12-23 07:00AM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire) -5.92%
06:59AM	Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results (Business Wire)
Apr-10-23 08:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-06-23 08:30AM	Industry Leader Tim Walbert Joins Mirum Pharmaceuticals Board of Directors (Business Wire)
Apr-05-23 08:30AM	Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis (Business Wire)
Apr-02-23 11:36AM	Top Growth Stocks for April 2023 (Investopedia)
Mar-31-23 06:39AM	Market Sentiment Around Loss-Making Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) (Simply Wall St.) +5.44%
Mar-15-23 09:05AM	Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up (Zacks)
Mar-14-23 08:30AM	Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older (Business Wire) +6.35%

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 27 '24	Buy	24.80	2,000	49,600	14,000	Mar 27 08:47 PM
Radovich Peter	PRESIDENT AND COO	Mar 25 '24	Sale	25.80	4,303	111,017	29,013	Mar 25 05:41 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 18 '24	Buy	25.80	2,000	51,600	12,000	Mar 18 05:34 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '24	Sale	26.19	6,013	157,491	104,112	Feb 05 09:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '24	Sale	26.19	1,790	46,883	34,695	Feb 05 09:05 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Feb 02 '24	Sale	26.19	1,214	31,797	28,691	Feb 05 09:12 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Feb 02 '24	Sale	26.19	847	22,184	104,407	Feb 05 09:10 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '24	Sale	26.19	735	19,251	1,759	Feb 02 09:28 PM
Peetz Christopher	PRESIDENT AND CEO	Jan 08 '24	Sale	28.03	5,209	146,033	110,125	Jan 09 08:12 PM
Radovich Peter	CHIEF OPERATING OFFICER	Jan 08 '24	Sale	28.03	1,408	39,473	36,485	Jan 09 08:28 PM
Vig Pamela	HEAD OF RESEARCH & DEVELOPMENT	Jan 08 '24	Sale	28.03	1,408	39,472	29,905	Jan 09 08:21 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Jan 08 '24	Sale	28.04	1,019	28,568	105,254	Jan 09 08:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 08 '24	Sale	28.04	528	14,803	722	Jan 09 08:09 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Option Exercise	2.94	2,500	7,350	2,500	Dec 06 05:16 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Sale	32.40	2,500	81,000	0	Dec 06 05:16 PM
GREY MICHAEL G	Director	Sep 14 '23	Option Exercise	2.94	14,216	41,738	14,216	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 14 '23	Sale	32.00	14,216	454,912	0	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 13 '23	Option Exercise	2.94	392	1,151	392	Sep 14 07:33 PM
Heron Patrick J	Director	Sep 13 '23	Buy	31.02	2,625	81,425	159,053	Sep 15 04:56 PM
GREY MICHAEL G	Director	Sep 13 '23	Sale	32.00	392	12,544	0	Sep 14 07:33 PM
Heron Patrick J	Director	Sep 12 '23	Buy	30.60	3,750	114,764	156,428	Sep 13 04:39 PM
BJERKHOLT ERIC	Chief Financial Officer	Sep 11 '23	Buy	29.65	10,000	296,492	10,000	Sep 12 06:23 PM
Heron Patrick J	Director	Sep 11 '23	Buy	30.30	4,687	142,027	152,678	Sep 13 04:39 PM
Heron Patrick J	Director	Aug 31 '23	Buy	26.25	147,991	3,884,764	147,991	Sep 05 12:51 PM
Howe Jolanda	SVP, Global Controller	Aug 25 '23	Sale	26.23	3,459	90,743	0	Aug 28 04:30 PM
Peetz Christopher	President and CEO	Jul 03 '23	Sale	25.65	5,498	141,005	115,334	Jul 05 07:30 PM
Radovich Peter	Chief Operating Officer	Jul 03 '23	Sale	25.65	1,425	36,546	37,675	Jul 05 07:47 PM
Vig Pamela	Head of Research & Development	Jul 03 '23	Sale	25.65	1,425	36,546	30,786	Jul 05 07:35 PM
Longpre Lara	Chief Development Officer	Jul 03 '23	Sale	25.65	1,004	25,749	105,839	Jul 05 07:37 PM
Howe Jolanda	SVP, Global Controller	Jul 03 '23	Sale	25.65	915	23,467	3,459	Jul 05 07:33 PM
GREY MICHAEL G	Director	Jun 08 '23	Option Exercise	2.94	14,608	42,889	14,608	Jun 09 04:20 PM
GREY MICHAEL G	Director	Jun 08 '23	Sale	29.00	14,608	423,632	0	Jun 09 04:20 PM
GREY MICHAEL G	Director	May 03 '23	Option Exercise	2.94	14,608	42,889	14,608	May 04 09:58 PM
GREY MICHAEL G	Director	May 03 '23	Sale	28.00	14,608	409,024	0	May 04 09:58 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ADVM

Adverum Biotechnologies Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience